Literature DB >> 30253056

Cardiovascular risk factors in non-alcoholic fatty liver disease.

Hannes Hagström1,2, Patrik Nasr3,4, Mattias Ekstedt3,4, Ulf Hammar5, Per Stål1,6, Johan Askling2, Rolf Hultcrantz1,6, Stergios Kechagias3,4.   

Abstract

BACKGROUND & AIMS: Patients with non-alcoholic fatty liver disease (NAFLD) are at an increased risk for cardiovascular disease (CVD). It is unclear whether histological variables may help predict CVD risk. We evaluated histology and traditional CV risk factors as predictors of CVD outcomes in a large NAFLD cohort.
METHODS: We included 603 biopsy-proven NAFLD patients free of baseline CVD and matched these (1:10, by age, sex and municipality) to 6269 population controls. All individuals were cross-linked to national registries to ascertain incident CVD events, defined as acute ischaemic heart disease or stroke. The presence of CV risk factors and liver histology were available in NAFLD patients only. Cox regression models were used to estimate hazard ratios (HR) for incident CVD.
RESULTS: During a mean follow-up of 18.6 years, 168 (28%) of NAFLD patients and 1325 (21%) of controls experienced a CVD event (HR 1.54, 95%CI 1.30-1.83). Within the NAFLD cohort, age, male sex, type 2 diabetes, smoking and triglycerides were associated with risk of CVD. Taking these CV risk factors into account, no histological parameter, including presence of NASH and fibrosis stage, were associated with incident CVD.
CONCLUSIONS: Patients with NAFLD are at an increased risk for CVD compared to matched controls, but histological parameters do not seem to independently predict this risk.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiovascular disease; epidemiology; fatty liver; hepatic fibrosis; non-alcoholic steatohepatitis

Year:  2018        PMID: 30253056     DOI: 10.1111/liv.13973

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  24 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

Review 2.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

3.  Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.

Authors:  Jacqueline B Henson; Tracey G Simon; Alyson Kaplan; Stephanie Osganian; Ricard Masia; Kathleen E Corey
Journal:  Aliment Pharmacol Ther       Date:  2020-02-11       Impact factor: 8.171

Review 4.  Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.

Authors:  Sneha Kothari; Hiteshi Dhami-Shah; Samir R Shah
Journal:  J Clin Exp Hepatol       Date:  2019-06-27

Review 5.  The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.

Authors:  Cyrielle Caussy; Adrien Aubin; Rohit Loomba
Journal:  Curr Diab Rep       Date:  2021-03-19       Impact factor: 4.810

6.  Beyond traditional cardiovascular risk factors: Could frailty and other morbidities explain the worse prognosis in patients undergoing pharmacologic stress?

Authors:  Patricia Rodriguez Lozano; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2020-11-25       Impact factor: 5.952

7.  Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease.

Authors:  Nobuharu Tamaki; Mayu Higuchi; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-16       Impact factor: 13.576

Review 8.  Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.

Authors:  Amedeo Lonardo; Ayako Suzuki
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

9.  The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers.

Authors:  Nicolette Veracruz; Bilal Hameed; Sammy Saab; Robert J Wong
Journal:  J Clin Exp Hepatol       Date:  2020-05-20

10.  Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.

Authors:  Michelle T Long; Xiaoyu Zhang; Hanfei Xu; Ching-Ti Liu; Kathleen E Corey; Raymond T Chung; Rohit Loomba; Emelia J Benjamin
Journal:  Hepatology       Date:  2021-02-06       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.